Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

van de Vooren K, Duranti S, Curto A, Garattini L.

Pharmacoeconomics. 2014 Jan;32(1):29-45. doi: 10.1007/s40273-013-0113-y. Review.

PMID:
24288207
2.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
3.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

4.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
5.

Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools.

Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A, Edmunds JW, Beutels P.

BMC Med. 2011 May 12;9:53. doi: 10.1186/1741-7015-9-53.

6.

The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.

Giglio N, Micone P, Gentile A.

Vaccine. 2011 Sep 14;29 Suppl 3:C35-42. doi: 10.1016/j.vaccine.2011.06.095. Review.

PMID:
21896351
7.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

8.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
9.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
10.

Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.

Hoshi SL, Kondo M, Okubo I.

Vaccine. 2013 Jun 7;31(25):2762-71. doi: 10.1016/j.vaccine.2013.03.052. Epub 2013 Apr 13.

PMID:
23588088
11.

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England.

van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M.

Vaccine. 2012 Nov 26;30(50):7205-13. doi: 10.1016/j.vaccine.2012.10.017. Epub 2012 Oct 23.

PMID:
23084850
12.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M.

Value Health. 2004 Jan-Feb;7(1):36-51.

13.

Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.

Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Abo Freikha S, Hoestlandt C, Lara C, Hajjeh R, Munier A.

Vaccine. 2015 May 7;33 Suppl 1:A182-91. doi: 10.1016/j.vaccine.2014.12.044.

PMID:
25919159
14.

Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.

Komakhidze T, Hoestlandt C, Dolakidze T, Shakhnazarova M, Chlikadze R, Kopaleishvili N, Goginashvili K, Kherkheulidze M, Clark AD, Blau J.

Vaccine. 2015 May 7;33 Suppl 1:A219-26. doi: 10.1016/j.vaccine.2014.12.070.

PMID:
25919165
15.

Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).

Wu DB, Chaiyakunapruk N, Chong HY, Beutels P.

Vaccine. 2015 Mar 30;33(14):1633-58. doi: 10.1016/j.vaccine.2015.01.081. Epub 2015 Feb 11. Review.

PMID:
25681663
16.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
17.

TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.

Clark A, Jauregui B, Griffiths U, Janusz CB, Bolaños-Sierra B, Hajjeh R, Andrus JK, Sanderson C.

Vaccine. 2013 Jul 2;31 Suppl 3:C19-29. doi: 10.1016/j.vaccine.2013.05.045.

PMID:
23777686
18.
19.

Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey.

Türel O, Kisa A, McIntosh ED, Bakir M.

Value Health. 2013 Jul-Aug;16(5):755-9. doi: 10.1016/j.jval.2013.03.1632. Epub 2013 Jul 10.

20.

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.

Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB.

Pediatr Infect Dis J. 2006 Jun;25(6):494-501.

PMID:
16732146

Supplemental Content

Support Center